PMID- 32909092
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 1432-1963 (Electronic)
IS  - 0172-8113 (Linking)
VI  - 41
IP  - 6
DP  - 2020 Nov
TI  - [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell 
      lymphomas].
PG  - 574-581
LID - 10.1007/s00292-020-00816-6 [doi]
AB  - The introduction of new lymphoma entities that are defined by chromosomal 
      rearrangements has led to changes concerning the diagnostic algorithms in routine 
      hematopathology, particularly for the large group of aggressive B‑cell lymphomas. 
      The new, genetically defined entity high-grade B‑cell lymphoma with MYC and BCL2 
      and/or BCL6 rearrangements (double/triple hit lymphoma) is morphologically 
      heterogenous and comprises lymphomas with the morphology of a diffuse large 
      B‑cell lymphoma (DLBCL), but also cases with blastoid appearance as well as 
      intermediate/Burkitt-like morphology. This implies a cytogenetic analysis for the 
      final classification of aggressive lymphomas with DLBCL morphology, which 
      constitute the most common lymphomas in daily practice. This analysis is 
      currently most efficiently performed via a sequential fluorescence in situ 
      hybridization (FISH) approach, with an initial MYC-FISH, that is followed (if 
      required, i.e., if a MYC rearrangement is detected) by an analysis regarding 
      a BCL2- and BCL6-chromosomal rearrangement. In addition, the update of the fourth 
      edition of the WHO classification for hematopoietic neoplasms introduced 
      additional lymphoma subgroups that are defined by chromosomal rearrangements, 
      such as Burkitt-like lymphoma with 11q aberration as well as large B cell 
      lymphoma with IRF4 rearrangement. Therefore, FISH currently plays an important 
      role in the diagnostic armamentarium in routine diagnostic hematopathology.
FAU - Gerhard-Hartmann, Elena
AU  - Gerhard-Hartmann E
AD  - Institut fur Pathologie, Universitat Wurzburg, Josef-Schneider-Strasse 2, 97080, 
      Wurzburg, Deutschland. Elena.Hartmann@uni-wuerzburg.de.
AD  - Comprehensive Cancer Center Mainfranken, Universitat Wurzburg, Wurzburg, 
      Deutschland. Elena.Hartmann@uni-wuerzburg.de.
FAU - Rosenwald, Andreas
AU  - Rosenwald A
AD  - Institut fur Pathologie, Universitat Wurzburg, Josef-Schneider-Strasse 2, 97080, 
      Wurzburg, Deutschland.
AD  - Comprehensive Cancer Center Mainfranken, Universitat Wurzburg, Wurzburg, 
      Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Fluoreszenz-in-situ-Hybridisierungen in der Diagnostik aggressiver 
      B-Zell-Lymphome.
PL  - Germany
TA  - Pathologe
JT  - Der Pathologe
JID - 8006541
RN  - 0 (BCL2 protein, human)
RN  - 0 (Interferon Regulatory Factors)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (interferon regulatory factor-4)
SB  - IM
MH  - Burkitt Lymphoma/*diagnosis/genetics
MH  - Chromosome Aberrations
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Interferon Regulatory Factors/genetics
MH  - Lymphoma, Large B-Cell, Diffuse/*diagnosis/genetics
MH  - Proto-Oncogene Proteins c-bcl-2/genetics
MH  - Proto-Oncogene Proteins c-bcl-6/genetics
MH  - Proto-Oncogene Proteins c-myc/genetics
MH  - Translocation, Genetic
OTO - NOTNLM
OT  - BCL2-translocation
OT  - BCL6-translocation
OT  - Burkitt lymphoma
OT  - FISH
OT  - High-grade B‑cell lymphoma
OT  - MYC rearrangement
EDAT- 2020/09/11 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/09/10 05:37
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
PHST- 2020/09/10 05:37 [entrez]
AID - 10.1007/s00292-020-00816-6 [pii]
AID - 10.1007/s00292-020-00816-6 [doi]
PST - ppublish
SO  - Pathologe. 2020 Nov;41(6):574-581. doi: 10.1007/s00292-020-00816-6.